RecruitingPhase 4NCT06433310

Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study


Sponsor

Weill Medical College of Cornell University

Enrollment

20 participants

Start Date

Oct 17, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to explore how the dietary supplement L-Phenylalanine affects the production of the metabolite phenylpropionic acid (PPA) and changes fungal populations of the gut microbiome.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Male or female adults over the age of 18 years

Exclusion Criteria6

  • History of a diagnosis of any gastrointestinal condition, such as inflammatory bowel syndrome or disease
  • Antibiotic usage within the past two weeks
  • Antifungal usage within the past month
  • Allergy to L-Phenylalanine or individuals with phenylketonuria (PKU)
  • Adults taking medications known to interact with L-phenylalanine supplements, such as Monoamine Oxidase Inhibitors (MOAI), L-DOPA, and some antipsychotic drugs (complete and extensive drug list will be provided to interested participants during screening)
  • Pregnant or nursing women

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGL-Phenylalanine 500 mg Veg Capsule product

500 mg Veg Capsule product


Locations(1)

Belfer Research Building

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06433310


Related Trials